LOGIN  |  REGISTER
Assertio
Compass Therapeutics

NextPlat Reports Third Quarter 2025 Results

November 13, 2025 | Last Trade: US$1.28 0.04 -3.03
  • Company Reports $13.8M in Q3 Revenue as Refocusing and Cost Cutting Initiatives Drive Improved Late Quarter Performance with Accelerated Sequential Improvements Expected in Q4 and into 2026 

HALLANDALE BEACH, Fla., Nov. 13, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced the financial results for the quarter-ended September 30, 2025, reflecting the performance of its e-Commerce and Healthcare Operations.

"Late in the third quarter, we began to see the positive impact of our cost-cutting, customer re-engagement, and business efficiency efforts, reversing the sequential declines witnessed in the first half of 2025. Based upon the significant increased prescription volumes and related revenue recorded in our healthcare segment in early Q4, combined with accelerating cost reductions across the organization, it is clear that our refocusing efforts are delivering the positive impacts we expected, laying the groundwork for much-improved financial results into early 2026," said David Phipps, Chief Executive Officer and President of NextPlat Corp.

Third Quarter 2025 Financial Highlights:

  • Consolidated revenue for the quarter ended September 30, 2025, was approximately $13.8 million compared to approximately $15.4 million for the quarter ended September 30, 2024. The decrease in consolidated revenue was primarily driven by a decline in Healthcare Operations due to the decrease in pharmacy 340B contract revenue. As a result of direct engagement with select 340B customers late in the quarter, the Company has seen improved prescription volume within this segment which it believes will contribute to sequential increases in 340B prescription volumes starting in the fourth quarter of 2025.

  • Overall gross profit margin for the quarter ended September 30, 2025, declined to approximately 19.9% from 23.2% when compared to the prior year quarter. Gross profit margin from our Healthcare segment decreased to approximately 18.4% in the third quarter of 2025 from 21.5% in the third quarter of 2024 and was primarily attributable to the decrease in 340B revenue. Gross profit margin for our e-Commerce Operations decreased to approximately 23.7% from 28.1% when compared to the prior year quarter primarily due to a service provider airtime contract that expired on December 31, 2024, which introduced new airtime costs beginning January 1, 2025, and temporary rate reductions for some customers continuing to be affected by ongoing network provider service interruptions.

  • Operating expenses for the quarter ended September 30, 2025, decreased to approximately $4.7 million compared to approximately $7.8 million in the prior year quarter, excluding approximately $3.7 million in non-recurring expenses such as an impairment loss from the write-down of certain long-lived assets. As expected, overall operational costs declined due to a decrease in stock-based compensation for grants fully vested, a reduction in executive compensation, and ongoing headcount reductions implemented as part of the Company's proactive steps designed to improve its expense structure. As a result of ongoing operational process efficiency improvements, staff adjustments, and other cost saving efforts, the Company anticipates further reductions in operating expenses which are expected to contribute to continued improvement going forward.

  • Net loss attributable to NextPlat Corp common shareholders for the quarter ended September 30, 2025, decreased approximately 48% to approximately $2.2 million, or ($0.08) per diluted share, compared to a net loss of approximately $4.2 million, or ($0.22) per diluted share reported for the quarter ending September 30, 2024.

  • The Company ended the quarter with approximately $13.9 million in cash.

  • During the third quarter of 2025, the Company began repurchasing its common shares under the authorized share repurchase program. A total of 130,549 shares were repurchased and are being held as treasury stock.

Organizational Highlights and Recent Business Developments:

  • As communicated in the recent CEO Shareholder Update Letter, the Company continues to execute its plan to refocus and streamline its operations to improve efficiencies and reduce costs while supporting future growth. NextPlat has identified and taken steps to reduce annualized overhead expenses by more than $2.0 million through actions including reduction in staff, operational and logistical improvements, and the elimination of underutilized office space. Although some of these initial cost reductions are included in the financial results for the quarter ended September 30, 2025, the identified savings are expected to increasingly contribute to sequentially improved operating metrics starting in the fourth quarter. At the same time, the Company is allocating a portion of these annual savings to invest into supporting the growth of the business including improved customer service and the recruitment of additional personnel and resources in sales and marketing with an emphasis on securing new 340B and long-term care facility service contracts.

  • Under the leadership of its newly expanded Healthcare team, the Company has been implementing operational improvements focused on efficiency, enhanced customer service, and business development. These efforts are highlighted by the addition of new customers during the quarter as well as a recently expanded medication fulfillment services subcontract on behalf of a government contractor previously awarded to the Company. This subcontract and renewed activity by new and existing 340B customers are contributing to a significant increase in additional high margin prescription volumes, currently exceeding 3,000+ per month. This increased activity and momentum continued through October and into early November and is currently anticipated to drive a significant sequential prescription volume increase in the fourth quarter vs. the third quarter of 2025 and into 2026. The Company is also currently working to optimize inventory levels in its PharmcoRx pharmacies, which are expected to generate a significant one-time cash savings through the return of excess inventory to the supplier.

  • In the e-Commerce segment, during the quarter, the Company continued to see robust sales for satellite-based connectivity and IoT (Internet of Things) products with strength on the Amazon platform and in high-margin recurring revenue which continues to run at record levels. Through its Global Telesat Communications Ltd (GTC) and U.S.-based Orbital Satcom and Outfitter Satellite units, the Company continues to expand its portfolio of cutting-edge connectivity products and growing its consumer and enterprise customer base with new and existing relationships, highlighted by the selection of GTC as the exclusive distributor for personal messaging and tracking products by a leading global satellite network operator for countries in the Nordic region. In its e-Commerce development program for the sale of OPKO Healthcare (NASDAQ: OPK) ("OPKO")-branded human health and wellness products in China, despite continued challenges of limited inventory levels, sales activity and sell-through remains high. In September, NextPlat also launched its Florida Sunshine products in the UK and EU and began processing orders via its Amazon and Shopify e-commerce storefronts. The Company is also preparing the launch of an Artificial Intelligence (AI)-driven marketing campaign for Florida Sunshine in partnership with an experienced healthcare brand marketing firm and its storefront on Alibaba Group Holding Limited's (NYSE: BABA) Tmall store in China has been approved to sell its products with shipping expected to begin in the first quarter of 2026.

Third Quarter 2025 Conference Call Notification

NextPlat's Chief Executive Officer and President, David Phipps, its Chief Financial Officer, Amanda Ferrio, and Vice President of Healthcare Operations, Birute Norkute, will host a conference call today, November 13th at 8:30 a.m. Eastern time to discuss the results for the quarter ended September 30, 2025, as well as other recent developments.

To access the call, please use the following information:

Date:

Thursday, November 13, 2025

Time:

8:30 a.m. Eastern time

Toll-free dial-in number:

1-800-836-8184

International dial-in number:

1-646-357-8785

Conference webcast link:

https://app.webinar.net/EYVam5wPR3y

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization.

The conference call will be broadcast live and available for replay at https://app.webinar.net/EYVam5wPR3y and via the investor relations section of the Company's website at https://ir.nextplat.com/news-events/ir-calendar/detail/20251113-q3-2025-results-conference-call. A replay of the conference call will be available after 12:00 p.m. Eastern time through November 20, 2025.

Toll-free replay number:

 1-888-660-6345

International replay number:

 1-646-517-4150

Replay entry code:

 03432 #

The financial information included in this press release should be read in conjunction with the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the Securities and Exchange Commission.

About NextPlat Corp

NextPlat is a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide. Through acquisitions, joint ventures and collaborations, the Company seeks to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-Commerce presence and revenue. NextPlat currently operates an e-Commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care.

Forward-Looking Statements

Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company's business and any of its products, services or solutions. The words "believe," "forecast," "project," "intend," "expect," "plan," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, including the Company's ability to launch additional e-commerce capabilities for consumer and healthcare products  and its ability to grow and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company's previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release.

Media and Investor Contact for NextPlat Corp:

Michael Glickman
MWGCO, Inc.
917-397-2272
This email address is being protected from spambots. You need JavaScript enabled to view it.

NEXTPLAT CORP AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands, except per share data)

(Unaudited)

 
  

Three Months Ended September
30,

  

Nine Months Ended September
30,

 
  

2025

  

2024

  

2025

  

2024

 

Sales of products, net

 

$

13,099

  

$

12,865

  

$

38,444

  

$

41,015

 

Revenues from services

  

653

   

2,502

   

3,073

   

8,834

 

Revenue, net

  

13,752

   

15,367

   

41,517

   

49,849

 
                 

Cost of products

  

11,012

   

11,799

   

32,410

   

35,539

 

Cost of services

  

10

   

10

   

31

   

31

 

Cost of revenue

  

11,022

   

11,809

   

32,441

   

35,570

 
                 

Gross profit

  

2,730

   

3,558

   

9,076

   

14,279

 
                 

Operating expenses:

                

Selling, general and administrative

  

1,510

   

1,728

   

4,415

   

4,650

 

Salaries, wages and payroll taxes

  

2,665

   

3,478

   

7,929

   

10,293

 

Impairment loss

  

   

3,729

   

   

13,653

 

Professional fees

  

389

   

2,144

   

1,509

   

4,133

 

Depreciation and amortization

  

130

   

197

   

450

   

608

 

Intangible asset amortization

  

25

   

281

   

76

   

1,679

 

Total operating expenses

  

4,719

   

11,557

   

14,379

   

35,016

 
                 

Loss before other (income) expense

  

(1,989)

   

(7,999)

   

(5,303)

   

(20,737)

 
                 

Other (income) expense:

                

Loss (gain) on sale or disposal of property and equipment

  

36

   

(98)

   

199

   

(98)

 

Loss on settlement of litigation

  

250

   

   

250

   

 

Interest expense

  

14

   

22

   

47

   

62

 

Interest earned

  

(88)

   

(183)

   

(295)

   

(596)

 

Other income

  

   

(2)

   

   

(2)

 

Foreign currency exchange rate variance

  

10

   

(119)

   

(201)

   

(87)

 

Total other (income) expense

  

222

   

(380)

   

   

(721)

 
                 

Loss before income taxes and non-controlling interest

  

(2,211)

   

(7,619)

   

(5,303)

   

(20,016)

 
                 

Income taxes

  

26

   

(45)

   

(14)

   

(92)

 

Net loss

  

(2,185)

   

(7,664)

   

(5,317)

   

(20,108)

 
                 

Net loss attributable to non-controlling interest

  

   

3,448

   

   

9,100

 

Net loss attributable to NextPlat Corp

 

$

(2,185)

  

$

(4,216)

  

$

(5,317)

  

$

(11,008)

 
                 

Comprehensive loss:

                

Net loss

 

$

(2,185)

  

$

(7,664)

  

$

(5,317)

  

$

(20,108)

 

Foreign currency gain (loss)

  

18

   

6

   

(51)

   

(30)

 

Comprehensive loss

 

$

(2,167)

  

$

(7,658)

  

$

(5,368)

  

$

(20,138)

 
                 

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

 

$

(2,185)

  

$

(4,216)

  

$

(5,317)

  

$

(11,008)

 

Weighted number of common shares outstanding – basic and diluted

  

25,992

   

18,982

   

25,974

   

18,844

 
                 

Basic and diluted loss per share

 

$

(0.08)

  

$

(0.22)

  

$

(0.20)

  

$

(0.58)

 

NEXTPLAT CORP AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except number of shares and par value)

 
  

September 30, 2025

  

December 31, 2024

 
  

(Unaudited)

  

(Audited)

 

ASSETS

        

Current Assets

        

Cash

 

$

13,926

  

$

19,960

 

Accounts receivable, net

  

4,018

   

4,895

 

Receivables - other, net

  

1,716

   

732

 

Inventory, net

  

5,616

   

4,881

 

Unbilled revenue

  

306

   

237

 

VAT receivable

  

371

   

371

 

Prepaid expenses

  

256

   

404

 

Total Current Assets

  

26,209

   

31,480

 
         

Property and equipment, net

  

2,594

   

3,407

 
         

Goodwill

  

156

   

156

 

Intangible assets, net

  

448

   

524

 

Operating right-of-use assets, net

  

527

   

812

 

Finance right-of-use assets, net

  

   

5

 

Deposits

  

79

   

94

 

Total Other Assets

  

1,210

   

1,591

 

Total Assets

 

$

30,013

  

$

36,478

 
         

LIABILITIES AND EQUITY

        
         

Current Liabilities

        

Accounts payable and accrued expenses

 

$

6,437

  

$

7,230

 

Contract liabilities

  

243

   

89

 

Notes payable

  

252

   

380

 

Due to related party

  

4

   

48

 

Operating lease liabilities

  

356

   

404

 

Finance lease liabilities

  

   

5

 

Income taxes payable

  

71

   

54

 

Total Current Liabilities

  

7,363

   

8,210

 
         

Long Term Liabilities:

        

Notes payable, net of current portion

  

907

   

1,032

 

Operating lease liabilities, net of current portion

  

197

   

438

 

Total Liabilities

  

8,467

   

9,680

 
         

Commitments and Contingencies

  

   

 
         

Equity

        

Common stock ($0.0001 par value; 50,000,000 shares authorized, 26,224,987 and 25,963,051 shares issued
and outstanding as of September 30, 2025 and December 31, 2024, respectively)

  

3

   

3

 

Additional paid-in capital

  

75,913

   

75,697

 

Accumulated deficit

  

(54,267)

   

(48,950)

 

Accumulated other comprehensive loss

  

(117)

   

(66)

 

Treasury stock (at cost; 130,549 shares as of September 30, 2025 and no shares as of December 31, 2024,
respectively)

  

(100)

   

 

Equity attributable to NextPlat Corp stockholders

  

21,432

   

26,684

 

Equity attributable to non-controlling interests

  

114

   

114

 

Total Equity

  

21,546

   

26,798

 
         

Total Liabilities and Equity

 

$

30,013

  

$

36,478

 
Assertio

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page